Ranbaxy to provide generics in Germany under deal with AOK
This article was originally published in Scrip
Basics, a 100% subsidiary of Ranbaxy Laboratories, is to provide medicines in Germany following an agreement with AOK Baden-Wurttemberg. The agreement, which runs for two years, comes into effect on June 1st and includes Ranbaxy's cefaclor Basics (exclusive for all 15 AOK regional associations and five zones) and tamsulosin Basics (exclusive for 13 AOK regional associations and four zones ,with the exception of AOK Rhineland/Hamburg and AOK Westfalen Lippe zone). AOK is Germany's biggest health insurance group and its subscribers comprise nearly 24 million people.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.